AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 132 min read$PRLD

Prelude, Lilly Partner On Breast Cancer Combination Trial; Stock Up

Prelude Therapeutics (PRLD) and Eli Lilly (LLY) will collaborate on a clinical trial for PRT13722 combined with Verzenio and Inluriyo to treat HR+/HER2- breast cancer. The Phase 1 study is expected to begin in Q4 2026. PRLD stock rose 6.42% in pre-market trading after the announcement.

Original reporting
rttnews.com
Published Oct 13, 2026, 12:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Prelude, Lilly Partner On Breast Cancer Combination Trial; Stock Up — source image
Source · rttnews.com
Decision brief

The 30-second read

$PRLDBullishMed
01

Why it matters

The collaboration introduces a novel KAT6A degrader into a combination regimen, potentially differentiating Prelude's pipeline and providing Lilly with a new partner for breast‑cancer research.

02

Market read

First report of a new oncology trial partnership; could spark short‑term buying in PRLD and modest interest in LLY.

03

What to watch

Potential regulatory hurdles and competition from other CDK4/6 combos could limit upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Prelude Therapeutics is a micro‑cap biotech focused on epigenetic degraders; Eli Lilly is a large pharma with an established oncology franchise.

Company-level read

Ticker impact

$PRLDBullishHigh confidence
Context

Prelude Therapeutics announced a new clinical trial collaboration with Eli Lilly to test PRT13722 in breast cancer patients.

Expected impact

likely upward pressure on PRLD as investors price in potential future data; LLY may see modest support.

Evidence & confidence

First disclosure of a novel Phase 1 combination trial; clinical data can be material for a micro‑cap biotech.

$LLYNeutralHigh confidence
Context

Eli Lilly is partnering with Prelude Therapeutics on a breast‑cancer combination trial involving its drugs Verzenio and Inluriyo.

Expected impact

minor support or flat as the trial is early‑stage and represents limited revenue exposure.

Evidence & confidence

The collaboration is a new development but early‑stage; impact on a large pharma is limited.

Market effects

Sector

Adds to the pipeline of targeted breast‑cancer therapies, may boost biotech sentiment.

Regional

U.S. biotech investors may increase exposure to early‑stage trial plays.

Global

Limited to investors tracking oncology pipeline developments.

Counterpoint

What could challenge this read

The trial is early and may not translate into commercial value, so any price rally could be premature.

Key entities

  • Company
    Prelude Therapeutics

    Micro‑cap biotech developing PRT13722.

  • Company
    Eli Lilly

    Large pharmaceutical company providing Verzenio and Inluriyo.

Read at source← All news

StoryPrelude Therapeutics partners with Eli Lilly to supply drugs for Phase 1 breast cancer trial

Related articles

OCT 13
$PRLDMedAI 8/10

Prelude Therapeutics, Lilly Partner To Evaluate PRT13722 In Breast Cancer Trial

Prelude Therapeutics (PRLD) and Eli Lilly (LLY) will collaborate to evaluate PRT13722 in a breast cancer trial. The Phase 1 study will test PRT13722 with Lilly's Verzenio and Inluriyo in HR+/HER2- breast cancer patients. Prelude's IND application was cleared by the FDA, with enrollment expected in Q4 2026. Preclinical data showed PRT13722's potential as a monotherapy and in combination therapies. PRLD's stock closed at $3.74 on Monday, up 6.42% in pre-market trading.

rttnews.com2 min
OCT 12
$LLYMed

Lilly reports Phase IIIb data on Taltz and Zepbound combination

Eli Lilly reported Phase IIIb trial results showing that combining Taltz and Zepbound alters more immune and metabolic biomarkers than Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity. The 52-week trial involved 274 participants and analyzed biological responses through blood proteins and gene expression. By week 36, dual therapy shifted 482 proteins and 467 genes, compared with 140 proteins and 16 genes under monotherapy.

finance.yahoo.com2 min
OCT 11
$LLYLow

Eli Lilly Sued Over Alleged Digestive Complications From GLP-1 Medication

Eli Lilly faces a lawsuit from a North Carolina man who claims its GLP-1 medications caused gastroparesis and inadequate warning labels. The plaintiff seeks compensation for medical expenses and damages. Lilly defends its safety monitoring and labeling practices, citing FDA-approved warnings. The case involves Mounjaro, a key Lilly product. The allegations are unproven.

inkfreenews.com2 min
OCT 9
$LLYLow

Ixekizumab, Tirzepatide Broaden Biomarker Effects in Psoriasis, Obesity

Eli Lilly reported that a combination of ixekizumab (Taltz) and tirzepatide (Zepbound) showed broader changes in psoriasis, immune, and metabolic biomarkers than ixekizumab alone in a phase 3b trial. The study, presented at a dermatology conference, suggests a link between psoriasis and obesity. Lilly noted that 61% of US psoriasis patients also have obesity or overweight with comorbidities. The combination therapy showed superior skin clearance and weight reduction in prior results.

hcplive.com2 min